The paper analyzes the latest recommendations of the American Thoracic Society and Infectious Diseases Society of America regarding the selection of antibacterial therapy for the treatment of non-hospital pneumonia, and also suggests the principle of prescribing drugs, taking into account the trends in the development of resistance in microorganisms. Also, considering the trends towards the development of antibiotic resistance in bacteria, the use of antibacterial therapy requires constant review. To do this, in this article, we turned to the WHO AWaRe 2019 classification, which can be used to more accurately select a safe and effective treatment for non-hospital pneumonia.
